糖尿病与非糖尿病维持性血液透析患者血管内皮生长因子与髓过氧化物酶的对比研究  

Contrast research of vascular endothelial growth factor and myeloperoxidase between diabetic and non-diabetic patients with maintenance hemodialysis

作　　者：李萌萌[1] 赵战云[2] 郭爱[1] 曹振昊 宋机光 

机构地区：[1]潍坊医学院研究生院,261000 [2]山东省潍坊市人民医院血液净化科,261000

出　　处：《中国医师进修杂志》2015年第5期359-362,共4页Chinese Journal of Postgraduates of Medicine

基　　金：山东省自然科学基金（y2007e114）

摘　　要：目的 研究糖尿病与非糖尿病维持性血液透析（MHD）患者血管内皮生长因子（VEGF）、髓过氧化物酶（MPO）水平是否存在差异,并探讨其是否与透析龄相关.方法 选择MHD患者120例,按患者原发病是否为糖尿病将其分为糖尿病组（40例）及非糖尿病组（80例）,收集患者入选时透析前的血液标本,检测血清VEGF、血浆MPO及其他生化指标.在2012年4月至2013年3月的血液标本标记为糖尿病1组（40例）、非糖尿病1组（80例）,2013年4月至2014年3月的血液标本标记为糖尿病2组（40例）、非糖尿病2组（80例）.结果 糖尿病1组VEGF（74.63±47.43）ng/L、MPO（300.63±235.37）μg/L,非糖尿病1组VEGF（63.69±43.23） ng/L、MPO（275.35±216.32）μg/L,两组VEGF、MPO比较差异有统计学意义（P＜0.05）;糖尿病2组VEGF（83.32±40.38） ng/L、MPO （414.12 ±265.52） μg/L,非糖尿病2组VEGF （70.89±39.74） ng/L、MPO （289.45±202.85）μg/L,两组VEGF、MPO比较差异有统计学意义（P＜0.05）.相关性分析结果显示,糖尿病1组和糖尿病2组VEGF与MPO水平均呈正相关（r=0.632和0.763,P＜0.05）,非糖尿病1组和非糖尿病2组VEGF与MPO水平也呈正相关（r=0.610和0.713,P＜0.05）.结论 糖尿病MHD患者VEGF、MPO的表达高于非糖尿病MHD患者;无论是糖尿病还是非糖尿病MHD患者,随着透析龄增长,VEGF、MPO表达水平逐渐升高;VEGF和MPO的表达互相关联.Objective To observe the difference of vascular endothelial growth factor （VEGF） and myeloperoxidase （MPO） between diabetic and non-diabetic patients with maintenance hemodialysis （MHD）,and to explore whether it was associated with duration of hemodialysis.Methods A total of 120 patients with MHD were divided into diabetic group （40 cases） and non-diabetic group （80 cases） according to the primary disease.The blood samples from the patients before dialysis were selected to test the serum VEGF and plasma MPO and other indicators.The blood samples from April 2012 to March 2013 were labeled diabetic group 1（40 cases） and non-diabetic group 1 （80 cases）.The blood samples from April 2013 to March 2014 were labeled diabetic group 2 （40 cases） and non-diabetic group 2 （80 cases）.Results The serum VEGF and plasma MPO levels were （74.63 ± 47.43） ng/L,（300.63 ± 235.37） μ g/L in diabetic group 1,and （63.69 ± 43.23） ng/L,（275.35 ± 216.32） μ g/L in non-diabetic group 1,and there were significant differences between two groups （P 〈 0.05）.The serum VEGF and plasma MPO levels were （83.32 ± 40.38） ng/L,（414.12 ±265.52） μg/L in diabetic group 2,and （70.89 ±39.74） rig/L,（289.45 ±202.85） μg/L in non-diabetic group 2,and there were significant differences between two groups （P 〈 0.05）.The correlation analysis showed that VEGF was positively correlated with MPO in diabetic group 1 and diabetic group 2 （r =0.632 and 0.763,P 〈 0.05）,and VEGF was positively correlated with MPO in non-diabetic group 1 and non-diabetic group 2 （r =0.610 and 0.713,P 〈 0.05）.Conclusions Compared with those in non-diabetic MHD patients,VEGF and MPO levels are significandy higher in diabetic MHD patients.In non-diabetic MHD patients and diabetic MHD patients,VEGF and MPO levels will rise gradually with duration of hemodialysis.The expressions of VEGF and MPO are associated with each other.

关 键 词：血液透析 内皮生长因子 髓过氧化物酶 

分 类 号：R587.2[医药卫生—内分泌] R692.5[医药卫生—内科学]